Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

1.550 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.500 (3,000)
Ask (Size) 1.640 (500)
Prev. Close 1.550
Today's Range 1.550 - 1.550
52wk Range 1.260 - 5.200
Shares Outstanding 105,482,558
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MaxCyte Announces Planned CFO Transition in 2026
Company initiates search for successor 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
-4.9%
-4.9%
3 Month
-3.1%
-3.1%
6 Month
-30.8%
-30.8%
1 Year
-62.7%
-62.7%

More News

Read More
News headline image
Earnings Scheduled For November 12, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
Via Benzinga
News headline image
A Look at MaxCyte's Upcoming Earnings Report ↗
Via Benzinga
News headline image
Insights into MaxCyte's Upcoming Earnings ↗
Via Benzinga
News headline image
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
From MaxCyte, Inc
Via GlobeNewswire
News headline image
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
Via Benzinga
News headline image
Thursday's session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
MaxCyte (MXCT) Q2 Revenue Drops 18% ↗
Via The Motley Fool
News headline image
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Signs Platform License Agreement with Adicet Bio
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
From MaxCyte, Inc
Via GlobeNewswire

Frequently Asked Questions

Is MaxCyte, Inc. - Common Stock publicly traded?
Yes, MaxCyte, Inc. - Common Stock is publicly traded.
What exchange does MaxCyte, Inc. - Common Stock trade on?
MaxCyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MaxCyte, Inc. - Common Stock?
The ticker symbol for MaxCyte, Inc. - Common Stock is MXCT on the Nasdaq Stock Market
What is the current price of MaxCyte, Inc. - Common Stock?
The current price of MaxCyte, Inc. - Common Stock is 1.550
When was MaxCyte, Inc. - Common Stock last traded?
The last trade of MaxCyte, Inc. - Common Stock was at 12/31/25 04:00 PM ET
What is the market capitalization of MaxCyte, Inc. - Common Stock?
The market capitalization of MaxCyte, Inc. - Common Stock is 163.50M
How many shares of MaxCyte, Inc. - Common Stock are outstanding?
MaxCyte, Inc. - Common Stock has 163M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.